<br><div class="old-content"><style></style><div class="old-content"><div class="old-content"><strong> </strong></div><div class="old-content"><strong>Optibrium Ltd. </strong><div class="old-content"><div class="old-content"> </div><div class="old-content">Optibrium, a developer of software for drug discovery, todayannounced that AstraZeneca has signed an agreement to license Optibrium'sStarDrop software.  The agreement willsee the global deployment of StarDrop and the ADME-QSAR and Auto-Modellermodules to AstraZeneca's researchers. StarDrop is a software suite that helpsto deliver optimally balanced, effective drugs. By quickly highlightingdiverse, high-quality compounds, StarDrop dramatically reduces the time ittakes to find effective leads and then transform them into candidate drugs,which will have a high probability of success downstream.</div><div class="content-inline-widget-lead-gen @container clear-both mx-auto my-6 mb-10 max-w-[710px] overflow-auto"><div class="text-ad flex justify-center pb-3 text-xs font-normal">Continue reading below...</div><div class="flex flex-col overflow-hidden rounded-lg border @lg:flex-row"><a class="@lg:border-r-primary flex-shrink-0 overflow-hidden no-underline @lg:border-r-8" data-gtm="{&quot;event&quot;:&quot;inline-lead-click&quot;,&quot;clickedArticleId&quot;:16471,&quot;clickedArticleCategory&quot;:&quot;internal-medicine&quot;,&quot;generationType&quot;:&quot;auto&quot;,&quot;clickUrl&quot;:&quot;https://www.drugdiscoverynews.com/accelerating-rare-disease-clinical-trials-16471&quot;}" href="/accelerating-rare-disease-clinical-trials-16471" rel="noopener" target="_blank"><img alt="Illustration of diverse healthcare professionals interacting with digital medical data and health records on virtual screens." class="aspect-theme object-cover transition-transform duration-500 hover:scale-[1.025] @lg:aspect-square @lg:max-w-48" fetchpriority="lazy" height="176" loading="lazy" src="https://cdn.drugdiscoverynews.com/assets/image/4117/81781-webinar-natera-august-19th-kr1800x900-plain-istock-s.webp" width="176"></a><div class="m-4 flex flex-col items-start gap-4 @lg:gap-2.5"><a class="link text-sm sm:text-sm inline no-underline hover:underline" href="/type/webinars" target="_self"><svg aria-hidden="true" focusable="false" data-prefix="far" data-icon="book" class="svg-inline--fa fa-book " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M0 88C0 39.4 39.4 0 88 0L392 0c30.9 0 56 25.1 56 56l0 288c0 22.3-13.1 41.6-32 50.6l0 69.4 8 0c13.3 0 24 10.7 24 24s-10.7 24-24 24L80 512c-44.2 0-80-35.8-80-80c0-2.7 .1-5.4 .4-8L0 424 0 88zM80 400c-17.7 0-32 14.3-32 32s14.3 32 32 32l288 0 0-64L80 400zM48 358.7c9.8-4.3 20.6-6.7 32-6.7l312 0c4.4 0 8-3.6 8-8l0-288c0-4.4-3.6-8-8-8L88 48C65.9 48 48 65.9 48 88l0 270.7zM152 112l176 0c13.3 0 24 10.7 24 24s-10.7 24-24 24l-176 0c-13.3 0-24-10.7-24-24s10.7-24 24-24zm0 80l176 0c13.3 0 24 10.7 24 24s-10.7 24-24 24l-176 0c-13.3 0-24-10.7-24-24s10.7-24 24-24z"></path></svg>Webinars</a><a class="text-body line-clamp-3 text-lg leading-6 font-bold no-underline hover:underline @lg:line-clamp-2 @lg:leading-5" data-gtm="{&quot;event&quot;:&quot;inline-lead-click&quot;,&quot;clickedArticleId&quot;:16471,&quot;clickedArticleCategory&quot;:&quot;internal-medicine&quot;,&quot;generationType&quot;:&quot;auto&quot;,&quot;clickUrl&quot;:&quot;https://www.drugdiscoverynews.com/accelerating-rare-disease-clinical-trials-16471&quot;}" href="/accelerating-rare-disease-clinical-trials-16471" rel="noopener" target="_blank">Accelerating rare disease clinical trials</a><div class="text-muted line-clamp-3 text-sm leading-5 font-light break-words @lg:line-clamp-2 @lg:leading-4.5">Explore how a rare kidney disease trial achieved faster patient enrollment with data-informed strategies and collaborative partnerships.</div><a class="btn btn-theme-primary btn-size-medium flex-wrap mt-auto no-underline" data-gtm="{&quot;event&quot;:&quot;inline-lead-click&quot;,&quot;clickedArticleId&quot;:16471,&quot;clickedArticleCategory&quot;:&quot;internal-medicine&quot;,&quot;generationType&quot;:&quot;auto&quot;,&quot;clickUrl&quot;:&quot;https://www.drugdiscoverynews.com/accelerating-rare-disease-clinical-trials-16471&quot;}" href="/accelerating-rare-disease-clinical-trials-16471" rel="noopener" target="_blank">Read More</a></div></div></div><div class="old-content"> </div><div class="old-content"><div class="old-content"><strong>Optibrium Ltd.</strong><div class="old-content"><br><a href="http://www.optibrium.com/ " target="_blank">www.optibrium.com</a><div class="old-content">  </div></div></div></div></div><div class="old-content"><div class="old-content"></div></div></div> </div></div>

October 2013

Optibrium, a developer of software for drug discovery, today announced that AstraZeneca has 

signed an agreement to license Optibrium’s StarDrop software. 

Internal Medicine

 Optibrium and 

AstraZeneca sign agreement for global license of StarDrop

Article

Articles

ddn-front-cover-december-issue-2025

December 2025

Research Areas

A 3D molecular visualization of antibody-like protein structures with attached yellow payloads floating against a dark, space-like background.

istock-1715913285-1800x900-1

xdc-logo-01-1

Evolving approaches to conjugation chemistry and linker&ndash;payload design are helping address persistent challenges in bioconjugate development.

Advancing bioconjugate development through innovative approaches

Whitepaper

Fluorescent-style illustration of spherical embryonic stem cells clustered together against a dark background.

87742-january-13th-webinar-lonza-kr1800x900-plain-istock

35-lonza-logo

Lonza

Explore how emerging <em>in vitro</em> systems &mdash; built from primary cells, cocultures, and vascularized tissues &mdash; are improving translational research outcomes.&nbsp;

Advancing predictive <em id="isPasted">in vitro</em> models

Webinars

3D illustration of ciliated cells, with cilia shown in blue.

istock-956478190-1800x900

picture14

Syncell

Ultraprecise proteomic analysis reveals new insights into the molecular machinery of cilia.

Mapping the hidden proteome of elusive organelles

Application Note

Optibrium Ltd. Optibrium, a developer of software for drug discovery, todayannounced that AstraZeneca has signed an agreement to license Optibrium'sStarDrop software.  The agreement willsee the global deployment of StarDrop and the ADME-QSAR and Auto-Modellermodules to AstraZeneca's researchers. StarDrop is a software suite that helpsto deliver optimally balanced, effective drugs. By quickly highlightingdiverse, high-quality compounds, StarDrop dramatically reduces the time ittakes to find effective leads and then transform them into candidate drugs,which will have a high probability of success downstream. Optibrium Ltd. www.optibrium.com

Optibrium, a developer of software for drug discovery, today announced that AstraZeneca has 

signed an agreement to license Optibrium’s StarDrop software.

Optibrium and AstraZeneca sign agreement for global license of StarDrop

Related Topics

Published In

October 2013

Subscribe to our eNewsletters

Sponsored

December 2025